Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) shares are trading lower Monday morning, hitting a fresh 52-week low as investors weigh a new SEC filing alongside a biotech pipeline update from late last week. Here’s what investors need to know.
- Tonix Pharmaceuticals shares are approaching critical lows. Why did TNXP hit a new low?
Reverse Split Proposal Adds New Pressure On Tonix Shares
In a definitive proxy statement filed Monday, Tonix said shareholders will vote at its May 7 annual meeting on several key proposals, including authorization for one or more reverse stock splits at an aggregate ratio ranging from 1-for-2 to 1-for-250, with timing and exact ratios left to the board’s discretion for up to two years after approval.
The filing also asks shareholders to approve a new 2026 Stock Incentive Plan, which the company said is intended to support recruiting, retention and performance goals.
That filing may be pressuring sentiment because reverse split proposals often signal efforts to maintain listing compliance and can amplify investor concerns around dilution and prolonged share-price weakness.
TNX-1900 Study Progress Offers Pipeline Update Amid Selloff
Last Thursday, Tonix announced the first participant had been dosed in a Phase 1 investigator-initiated study of TNX-1900, its intranasal potentiated oxytocin candidate for migraine and craniofacial pain.
The company said the study will evaluate trigeminal nerve-mediated vasodilation and highlighted TNX-1900’s mechanism as distinct from existing CGRP-targeting migraine therapies.
TNXP RSI Heatmap: Analyzing Volatility And Oversold Trends
Over the past year, Tonix Pharmaceuticals’ (TNXP) Relative Strength Index (RSI) displayed significant volatility, repeatedly surging into overbought territory above 70 during the first half of the period.
More recently, the stock’s momentum has cooled considerably, briefly touching oversold levels before stabilizing in the lower-neutral zone by late March 2026.
TNXP Shares Slide Monday Morning
TNXP Price Action: Tonix Pharmaceuticals shares were down 5.51% at $12.18 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Image: Adobe Stock Images
Recent Comments